Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource

Edition: Fourth edition.

ISBN: 9781119211396 , 1119211395 , 9781119211402 , 1119211409 , 9781119211419 , 1119211417

Series Statement: Evidence-Based Medicine Ser.

Note: Intro; Evidence-Based Gastroenterology and Hepatology; Dedication; Contents; Contributors; Preface; PART I Gastrointestinal disorders; 1 Gastroesophageal reflux disease; Introduction; Definition of GERD; Clinical presentation; Epidemiology; Pathophysiology; Natural history and complications; Diagnostic tests; Symptom assessment and questionnaires; PPI trial; Upper GI endoscopy; Ambulatory GERD testing: pH and pH-impedance monitoring; Esophageal high-resolution manometry; Barium swallow; Mucosal impedance; Treatment; Lifestyle modifications; Antacids and alginates , Histamine-2 receptor antagonistsProton pump inhibitors; Potassium competitive acid blockers; Reflux inhibitors; Prokinetic drugs; Targeting hypersensitivity; Antireflux surgery; Novel surgical and endoscopic procedures; Conclusion; References; 2 Barretts esophagus; Introduction; Definition; Pathogenesis; Epidemiology; Incidence and prevalence; Risk factors; Natural history; Diagnosis; Endoscopy; Diagnosis-histopathology; Advanced endoscopic imaging in BE; Screening and surveillance; Screening; Surveillance; Treatment; Acid suppression , Chemoprevention of esophageal adenocarcinoma with anti-inflammatory agentsEndoscopic therapies for Barretts esophagus; Conclusion; References; 3 Esophageal motility disorders; Achalasia; Treatment of achalasia; Overview; Pharmacologic treatment; Botulinum toxin; Pneumatic dilation; Heller myotomy; Per-oral endoscopic myotomy (POEM); Comparisons among treatment modalities; Esophagectomy; Summary; Spastic motor disorders; Treatment of spastic motility disorders; Overview; Medications; Botulinum toxin; Pneumatic dilation; Heller myotomy; POEM; Summary; References; 4 Eosinophilic esophagitis , IntroductionSearching for the evidence; Definition; Etiology and pathogenesis; Genetics and genetic variants; Environmental factors; Epidemiology; Diagnosis; General approach and differential diagnosis; GERD and PPI-REE; Features in children; Features in adults; Endoscopic features; Histologic features; Prognosis and natural history; Management; Corticosteroids; Biologics; Leukotriene antagonists and mast cell stabilizers; Immunomodulators; Dietary therapy; Endoscopic management with dilation; Future advances; Evaluation and prognosis; Novel therapies; Summary of treatment data , AcknowledgmentsReferences; 5 Ulcer disease and Helicobacter pylori infection: current treatment; Introduction; What is the evidence for the role of H. pylori in peptic ulcer disease?; Association of H. pylori with ulcer disease (strength, consistency, and specificity); Duodenal ulcer; Duodenal ulcers not related to H. pylori and NSAIDs; Gastric ulcer; Temporal relationship; Biological gradient; Biological plausibility; Effects of interventions: outcomes following H. pylori eradication; Coherence of the data with earlier epidemiological information; Treatment of duodenal ulcer

Additional Edition: Print version: Evidence-based gastroenterology and hepatology. Hoboken, NJ : Wiley-Blackwell, 2019 ISBN 9781119211389

Language: English

Keywords: Textbooks. ; Textbooks. ; Textbooks.

URL: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119211419

URL: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119211419

URL: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119211419

UID:

Format: 1 online resource (814 pages)

Edition: Fourth edition.

ISBN: 1-119-21140-9 , 1-119-21139-5 , 1-119-21141-7

Note: Includes index. , Intro -- Evidence-Based Gastroenterology and Hepatology -- Dedication -- Contents -- Contributors -- Preface -- PART I Gastrointestinal disorders -- 1 Gastroesophageal reflux disease -- Introduction -- Definition of GERD -- Clinical presentation -- Epidemiology -- Pathophysiology -- Natural history and complications -- Diagnostic tests -- Symptom assessment and questionnaires -- PPI trial -- Upper GI endoscopy -- Ambulatory GERD testing: pH and pH-impedance monitoring -- Esophageal high-resolution manometry -- Barium swallow -- Mucosal impedance -- Treatment -- Lifestyle modifications -- Antacids and alginates -- Histamine-2 receptor antagonists -- Proton pump inhibitors -- Potassium competitive acid blockers -- Reflux inhibitors -- Prokinetic drugs -- Targeting hypersensitivity -- Antireflux surgery -- Novel surgical and endoscopic procedures -- Conclusion -- References -- 2 Barretts esophagus -- Introduction -- Definition -- Pathogenesis -- Epidemiology -- Incidence and prevalence -- Risk factors -- Natural history -- Diagnosis -- Endoscopy -- Diagnosis-histopathology -- Advanced endoscopic imaging in BE -- Screening and surveillance -- Screening -- Surveillance -- Treatment -- Acid suppression -- Chemoprevention of esophageal adenocarcinoma with anti-inflammatory agents -- Endoscopic therapies for Barretts esophagus -- Conclusion -- References -- 3 Esophageal motility disorders -- Achalasia -- Treatment of achalasia -- Overview -- Pharmacologic treatment -- Botulinum toxin -- Pneumatic dilation -- Heller myotomy -- Per-oral endoscopic myotomy (POEM) -- Comparisons among treatment modalities -- Esophagectomy -- Summary -- Spastic motor disorders -- Treatment of spastic motility disorders -- Overview -- Medications -- Botulinum toxin -- Pneumatic dilation -- Heller myotomy -- POEM -- Summary -- References -- 4 Eosinophilic esophagitis. , Introduction -- Searching for the evidence -- Definition -- Etiology and pathogenesis -- Genetics and genetic variants -- Environmental factors -- Epidemiology -- Diagnosis -- General approach and differential diagnosis -- GERD and PPI-REE -- Features in children -- Features in adults -- Endoscopic features -- Histologic features -- Prognosis and natural history -- Management -- Corticosteroids -- Biologics -- Leukotriene antagonists and mast cell stabilizers -- Immunomodulators -- Dietary therapy -- Endoscopic management with dilation -- Future advances -- Evaluation and prognosis -- Novel therapies -- Summary of treatment data -- Acknowledgments -- References -- 5 Ulcer disease and Helicobacter pylori infection: current treatment -- Introduction -- What is the evidence for the role of H. pylori in peptic ulcer disease? -- Association of H. pylori with ulcer disease (strength, consistency, and specificity) -- Duodenal ulcer -- Duodenal ulcers not related to H. pylori and NSAIDs -- Gastric ulcer -- Temporal relationship -- Biological gradient -- Biological plausibility -- Effects of interventions: outcomes following H. pylori eradication -- Coherence of the data with earlier epidemiological information -- Treatment of duodenal ulcer -- Influence of H. pylori eradication on healing of duodenal ulcer -- Acid suppressive therapy need not be continued beyond the duration of eradication treatment -- Duodenal ulcer complications and effects of H. pylori -- Bleeding -- Summary -- Perforation -- Obstruction -- Treatment of gastric ulcer -- H. pylori eradication influence on healing and recurrence of gastric ulcer -- H. pylori: eradication therapy -- Antibiotic regimens -- Important new updates -- Recommended first-line therapies -- Non-bismuth quadruple therapy -- Bismuth quadruple therapy -- Not recommended as first line. , Recommended treatments for prior treatment failure -- Bismuth quadruple therapy (PBMT) for 14 days -- PAL (PPI, amoxicillin and levofloxacin) for 14 days -- Last ditch rescue therapy: rifabutin regimens -- Probiotics in H. pylori eradication -- PPI (acid suppression) as part of the eradication regimen -- Acid suppression plus amoxicillin -- Summary -- References -- 6 Nonsteroidal anti-inflammatory drug-gastropathy and enteropathy -- Introduction -- Background -- Risk factors for NSAID-related gastrointestinal toxicity -- Do endoscopic ulcers predict clinical events? -- The role of Helicobacter pylori in NSAID-associated ulcers -- Ulcer healing -- Ulcer prevention in NSAID naive patients -- Secondary ulcer prevention in patients on continuous NSAID -- Definition of terms -- Misoprostol -- Long-term efficacy of misoprostol -- Endoscopic ulcers -- Analysis by dose -- Studies including data with less than three months' tNSAID exposure -- Clinical ulcers -- Adverse effects -- H2-receptor antagonists -- Treatment of NSAID-induced ulcer -- Prevention of NSAID-induced ulcers -- Symptoms -- Proton pump inhibitors -- Healing of ulcers with continued NSAID use -- NSAID ulcer prevention -- Symptoms -- Head-to-head comparisons -- Misoprostol vs. H2-RAs -- PPI vs. H2-RA -- PPI vs. misoprostol -- Symptoms -- Summary -- Cyclo-oxygenase-2 inhibitors -- Endoscopic ulcer trials -- Cyclo-oxygenase-2s vs. nonselective nonsteroidal anti-inflammatory drugs -- Endoscopically detected gastroduodenal ulcers -- Analysis by duration -- Analysis by cyclo-oxygenase-2 -- Celecoxib -- Etoricoxib -- Analysis by comparator nonsteroidal anti-inflammatory drugs -- Naproxen -- Ibuprofen -- Diclofenac -- Cyclo-oxygenase-2s vs. placebo -- Clinical gastrointestinal events -- Cyclo-oxygenase-2s vs. nonselective nonsteroidal anti-inflammatory drugs. , Analyses stratified by cyclo-oxygenase-2s -- Celecoxib -- Etoricoxib -- Analysis by comparator nonsteroidal anti-inflammatory drugs -- Cyclo-oxygenase-2s vs. placebo -- Influence of acetylsalicylic acid coadministration on clinically important ulcer complications -- Addition of a proton pump inhibitor to cyclo-oxygenase-2s -- Symptoms and treatment withdrawals -- Treatment withdrawals as a result of gastrointestinal side effects: cyclo-oxygenase-2s vs. nonselective nonsteroidal anti-inflammatory drugs -- Adverse gastrointestinal symptoms with cyclo-oxygenase-2s compared with nonselective nonsteroidal anti-inflammatory drugs -- Adverse gastrointestinal symptoms with cyclo-oxygenase-2s compared with placebo -- High-risk patients requiring NSAIDs -- Summary -- References -- 7 Acute non-variceal gastrointestinal hemorrhage: treatment -- Introduction -- Risk assessment -- Resuscitation and blood transfusion -- Correction of coagulaopthy -- Endoscopy -- Endoscopic therapy -- Single or dual modality? -- Adrenaline injection -- Alcohol -- Combination therapy with sclerosants -- Thrombin and fibrin glue -- Conclusion -- Thermal therapies -- Laser photocoagulation -- Heater probe -- Electrocoagulation -- Argon plasma coagulation -- Combination therapy with thermal modalities -- Mechanical hemostasis -- Hemoclips -- Triclip -- Combination therapy with mechanical modalities -- Endoscopic therapy for ulcers with adherent blood clot -- Elective repeat endoscopic therapy -- Failure of endoscopic therapy -- Endoscopic therapy: summary -- Endoscopic therapy in current practice -- Drug therapy -- Prokinetic agents -- Acid suppressing drugs -- Tranexamic acid -- Somatostatin and octreotide -- Test and treatment for Helicobacter pylori -- Conclusions -- References -- 8 Functional dyspepsia -- Introduction -- Definition of functional dyspepsia -- Overlap with GERD. , ROME IV functional dyspepsia criteria -- Making a functional dyspepsia diagnosis for clinical trials -- Methodological considerations in functional dyspepsia treatment trials -- Evidence for efficacious treatments -- Drug treatment -- Psycholgical therapies -- Other agents -- Conclusion -- References -- 9 Celiac disease: diagnosis, screening, and prognosis -- Epidemiology -- Pathophysiology and clinical manifestations -- Morbidity and mortality -- Age -- Gender -- Severity of disease -- Screening -- Small intestinal biopsy -- Therapies -- Future directions -- References -- 10 Therapy for Crohn's disease -- Introduction -- Therapies -- 5-Aminosalicylates -- Corticosteroids -- Conventional corticosteroids -- Budesonide -- Antibiotics -- Nitroimadazole antibiotics -- Fecal microbial transplant -- Probiotics -- Conventional immunosuppressive drugs -- Thiopurines -- Methotrexate (MTX) -- Cyclosporine -- Biologic therapies -- TNF antagonists -- Natalizumab -- Vedolizumab -- Investigational agents targeting lymphocyte trafficking -- Etrolizumab -- Anti-MAdCAM-1 therapy -- Ustekinumab -- p19 Inhibition -- Sphingosine-1-phosphate receptors antagonists (S1P1-5) -- Janus kinase inhibitors -- Mongersen -- Omega-3 fatty acids -- Combination therapy with TNF-antagonist antibodies and immunosuppressives for induction and maintenance of remission -- Conventional "step-up" vs. "top-down" approach to use of immunosuppressive agents for induction and maintenance of remission -- Summary -- Conclusions -- References -- 11 Ulcerative colitis -- Introduction -- Epidemiology -- Risk of cancer and surveillance -- Goal of treatment -- Treatment -- Aminosalicylates -- Corticosteroids -- Azathioprine and 6-mercaptopurine -- Methotrexate -- Cyclosporin -- Antitumor necrosis factor (TNF) monoclonal antibodies -- Anti-integrin monoclonal antibodies. , Novel therapies in late stage clinical development.

Additional Edition: ISBN 1-119-21138-7

Language: English

Keywords: Electronic books.

URL: Click to View

UID:

Format: 1 online resource (814 pages)

Edition: Fourth edition.

ISBN: 1-119-21140-9 , 1-119-21139-5 , 1-119-21141-7

Note: Includes index. , Intro -- Evidence-Based Gastroenterology and Hepatology -- Dedication -- Contents -- Contributors -- Preface -- PART I Gastrointestinal disorders -- 1 Gastroesophageal reflux disease -- Introduction -- Definition of GERD -- Clinical presentation -- Epidemiology -- Pathophysiology -- Natural history and complications -- Diagnostic tests -- Symptom assessment and questionnaires -- PPI trial -- Upper GI endoscopy -- Ambulatory GERD testing: pH and pH-impedance monitoring -- Esophageal high-resolution manometry -- Barium swallow -- Mucosal impedance -- Treatment -- Lifestyle modifications -- Antacids and alginates -- Histamine-2 receptor antagonists -- Proton pump inhibitors -- Potassium competitive acid blockers -- Reflux inhibitors -- Prokinetic drugs -- Targeting hypersensitivity -- Antireflux surgery -- Novel surgical and endoscopic procedures -- Conclusion -- References -- 2 Barretts esophagus -- Introduction -- Definition -- Pathogenesis -- Epidemiology -- Incidence and prevalence -- Risk factors -- Natural history -- Diagnosis -- Endoscopy -- Diagnosis-histopathology -- Advanced endoscopic imaging in BE -- Screening and surveillance -- Screening -- Surveillance -- Treatment -- Acid suppression -- Chemoprevention of esophageal adenocarcinoma with anti-inflammatory agents -- Endoscopic therapies for Barretts esophagus -- Conclusion -- References -- 3 Esophageal motility disorders -- Achalasia -- Treatment of achalasia -- Overview -- Pharmacologic treatment -- Botulinum toxin -- Pneumatic dilation -- Heller myotomy -- Per-oral endoscopic myotomy (POEM) -- Comparisons among treatment modalities -- Esophagectomy -- Summary -- Spastic motor disorders -- Treatment of spastic motility disorders -- Overview -- Medications -- Botulinum toxin -- Pneumatic dilation -- Heller myotomy -- POEM -- Summary -- References -- 4 Eosinophilic esophagitis. , Introduction -- Searching for the evidence -- Definition -- Etiology and pathogenesis -- Genetics and genetic variants -- Environmental factors -- Epidemiology -- Diagnosis -- General approach and differential diagnosis -- GERD and PPI-REE -- Features in children -- Features in adults -- Endoscopic features -- Histologic features -- Prognosis and natural history -- Management -- Corticosteroids -- Biologics -- Leukotriene antagonists and mast cell stabilizers -- Immunomodulators -- Dietary therapy -- Endoscopic management with dilation -- Future advances -- Evaluation and prognosis -- Novel therapies -- Summary of treatment data -- Acknowledgments -- References -- 5 Ulcer disease and Helicobacter pylori infection: current treatment -- Introduction -- What is the evidence for the role of H. pylori in peptic ulcer disease? -- Association of H. pylori with ulcer disease (strength, consistency, and specificity) -- Duodenal ulcer -- Duodenal ulcers not related to H. pylori and NSAIDs -- Gastric ulcer -- Temporal relationship -- Biological gradient -- Biological plausibility -- Effects of interventions: outcomes following H. pylori eradication -- Coherence of the data with earlier epidemiological information -- Treatment of duodenal ulcer -- Influence of H. pylori eradication on healing of duodenal ulcer -- Acid suppressive therapy need not be continued beyond the duration of eradication treatment -- Duodenal ulcer complications and effects of H. pylori -- Bleeding -- Summary -- Perforation -- Obstruction -- Treatment of gastric ulcer -- H. pylori eradication influence on healing and recurrence of gastric ulcer -- H. pylori: eradication therapy -- Antibiotic regimens -- Important new updates -- Recommended first-line therapies -- Non-bismuth quadruple therapy -- Bismuth quadruple therapy -- Not recommended as first line. , Recommended treatments for prior treatment failure -- Bismuth quadruple therapy (PBMT) for 14 days -- PAL (PPI, amoxicillin and levofloxacin) for 14 days -- Last ditch rescue therapy: rifabutin regimens -- Probiotics in H. pylori eradication -- PPI (acid suppression) as part of the eradication regimen -- Acid suppression plus amoxicillin -- Summary -- References -- 6 Nonsteroidal anti-inflammatory drug-gastropathy and enteropathy -- Introduction -- Background -- Risk factors for NSAID-related gastrointestinal toxicity -- Do endoscopic ulcers predict clinical events? -- The role of Helicobacter pylori in NSAID-associated ulcers -- Ulcer healing -- Ulcer prevention in NSAID naive patients -- Secondary ulcer prevention in patients on continuous NSAID -- Definition of terms -- Misoprostol -- Long-term efficacy of misoprostol -- Endoscopic ulcers -- Analysis by dose -- Studies including data with less than three months' tNSAID exposure -- Clinical ulcers -- Adverse effects -- H2-receptor antagonists -- Treatment of NSAID-induced ulcer -- Prevention of NSAID-induced ulcers -- Symptoms -- Proton pump inhibitors -- Healing of ulcers with continued NSAID use -- NSAID ulcer prevention -- Symptoms -- Head-to-head comparisons -- Misoprostol vs. H2-RAs -- PPI vs. H2-RA -- PPI vs. misoprostol -- Symptoms -- Summary -- Cyclo-oxygenase-2 inhibitors -- Endoscopic ulcer trials -- Cyclo-oxygenase-2s vs. nonselective nonsteroidal anti-inflammatory drugs -- Endoscopically detected gastroduodenal ulcers -- Analysis by duration -- Analysis by cyclo-oxygenase-2 -- Celecoxib -- Etoricoxib -- Analysis by comparator nonsteroidal anti-inflammatory drugs -- Naproxen -- Ibuprofen -- Diclofenac -- Cyclo-oxygenase-2s vs. placebo -- Clinical gastrointestinal events -- Cyclo-oxygenase-2s vs. nonselective nonsteroidal anti-inflammatory drugs. , Analyses stratified by cyclo-oxygenase-2s -- Celecoxib -- Etoricoxib -- Analysis by comparator nonsteroidal anti-inflammatory drugs -- Cyclo-oxygenase-2s vs. placebo -- Influence of acetylsalicylic acid coadministration on clinically important ulcer complications -- Addition of a proton pump inhibitor to cyclo-oxygenase-2s -- Symptoms and treatment withdrawals -- Treatment withdrawals as a result of gastrointestinal side effects: cyclo-oxygenase-2s vs. nonselective nonsteroidal anti-inflammatory drugs -- Adverse gastrointestinal symptoms with cyclo-oxygenase-2s compared with nonselective nonsteroidal anti-inflammatory drugs -- Adverse gastrointestinal symptoms with cyclo-oxygenase-2s compared with placebo -- High-risk patients requiring NSAIDs -- Summary -- References -- 7 Acute non-variceal gastrointestinal hemorrhage: treatment -- Introduction -- Risk assessment -- Resuscitation and blood transfusion -- Correction of coagulaopthy -- Endoscopy -- Endoscopic therapy -- Single or dual modality? -- Adrenaline injection -- Alcohol -- Combination therapy with sclerosants -- Thrombin and fibrin glue -- Conclusion -- Thermal therapies -- Laser photocoagulation -- Heater probe -- Electrocoagulation -- Argon plasma coagulation -- Combination therapy with thermal modalities -- Mechanical hemostasis -- Hemoclips -- Triclip -- Combination therapy with mechanical modalities -- Endoscopic therapy for ulcers with adherent blood clot -- Elective repeat endoscopic therapy -- Failure of endoscopic therapy -- Endoscopic therapy: summary -- Endoscopic therapy in current practice -- Drug therapy -- Prokinetic agents -- Acid suppressing drugs -- Tranexamic acid -- Somatostatin and octreotide -- Test and treatment for Helicobacter pylori -- Conclusions -- References -- 8 Functional dyspepsia -- Introduction -- Definition of functional dyspepsia -- Overlap with GERD. , ROME IV functional dyspepsia criteria -- Making a functional dyspepsia diagnosis for clinical trials -- Methodological considerations in functional dyspepsia treatment trials -- Evidence for efficacious treatments -- Drug treatment -- Psycholgical therapies -- Other agents -- Conclusion -- References -- 9 Celiac disease: diagnosis, screening, and prognosis -- Epidemiology -- Pathophysiology and clinical manifestations -- Morbidity and mortality -- Age -- Gender -- Severity of disease -- Screening -- Small intestinal biopsy -- Therapies -- Future directions -- References -- 10 Therapy for Crohn's disease -- Introduction -- Therapies -- 5-Aminosalicylates -- Corticosteroids -- Conventional corticosteroids -- Budesonide -- Antibiotics -- Nitroimadazole antibiotics -- Fecal microbial transplant -- Probiotics -- Conventional immunosuppressive drugs -- Thiopurines -- Methotrexate (MTX) -- Cyclosporine -- Biologic therapies -- TNF antagonists -- Natalizumab -- Vedolizumab -- Investigational agents targeting lymphocyte trafficking -- Etrolizumab -- Anti-MAdCAM-1 therapy -- Ustekinumab -- p19 Inhibition -- Sphingosine-1-phosphate receptors antagonists (S1P1-5) -- Janus kinase inhibitors -- Mongersen -- Omega-3 fatty acids -- Combination therapy with TNF-antagonist antibodies and immunosuppressives for induction and maintenance of remission -- Conventional "step-up" vs. "top-down" approach to use of immunosuppressive agents for induction and maintenance of remission -- Summary -- Conclusions -- References -- 11 Ulcerative colitis -- Introduction -- Epidemiology -- Risk of cancer and surveillance -- Goal of treatment -- Treatment -- Aminosalicylates -- Corticosteroids -- Azathioprine and 6-mercaptopurine -- Methotrexate -- Cyclosporin -- Antitumor necrosis factor (TNF) monoclonal antibodies -- Anti-integrin monoclonal antibodies. , Novel therapies in late stage clinical development.

Additional Edition: ISBN 1-119-21138-7

Language: English